| Myasthenia Gravis, Generalized

Vyvgart vs Soliris

Side-by-side clinical, coverage, and cost comparison for myasthenia gravis, generalized.
Deep comparison between: Vyvgart vs Soliris with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsSoliris has a higher rate of injection site reactions vs Vyvgart based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Soliris but not Vyvgart, including UnitedHealthcare
Sign up to reveal the full AI analysis
Vyvgart
Soliris
At A Glance
IV infusion
Once weekly for 4 weeks per cycle
FcRn antagonist
IV infusion
Every 2 weeks
Complement C5 inhibitor
Indications
  • Myasthenia Gravis, Generalized
  • Paroxysmal nocturnal hemoglobinuria
  • Atypical Hemolytic Uremic Syndrome
  • Myasthenia Gravis, Generalized
  • Neuromyelitis Optica
Dosing
Myasthenia Gravis, Generalized 10 mg/kg (1200 mg if >=120 kg) as IV infusion over 1 hour once weekly for 4 weeks; subsequent cycles based on clinical evaluation.
Paroxysmal nocturnal hemoglobinuria 600 mg IV infusion weekly for 4 weeks, then 900 mg at week 5, then 900 mg every 2 weeks thereafter.
Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized, Neuromyelitis Optica (adults) 900 mg IV infusion weekly for 4 weeks, then 1200 mg at week 5, then 1200 mg every 2 weeks thereafter.
Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized (pediatric) Weight-based IV infusion dosing; induction and maintenance doses vary by body weight (5 kg to >=40 kg), administered every 2 to 3 weeks after induction.
Contraindications
  • Serious hypersensitivity to efgartigimod alfa products or any excipient of VYVGART
  • Unresolved serious Neisseria meningitidis infection
Adverse Reactions
Most common (>=5%) Respiratory tract infection, headache, urinary tract infection, paraesthesia, myalgia
Postmarketing Hypersensitivity reactions including anaphylaxis and hypotension, infusion-related reactions
Most common (>=5%) Headache, nasopharyngitis, back pain, nausea, fatigue, cough, herpes simplex infections, sinusitis, upper respiratory tract infection, diarrhea, vomiting, hypertension, musculoskeletal pain, abdominal pain, peripheral edema, pyrexia, arthralgia, influenza, contusion
Serious Meningococcal infections, other serious infections, disease exacerbation after SOLIRIS discontinuation, thrombosis, infusion-related reactions
Postmarketing Fatal or serious infections (Neisseria gonorrhoeae, Neisseria meningitidis, Neisseria sicca/subflava, Neisseria spp unspecified), cholestatic or mixed pattern liver injury in aHUS patients
Pharmacology
Efgartigimod alfa-fcab is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), reducing circulating IgG levels and AChR autoantibody levels in patients with generalized myasthenia gravis.
Eculizumab is a monoclonal antibody that specifically binds complement protein C5 with high affinity, inhibiting its cleavage to C5a and C5b and preventing generation of the terminal complement complex C5b-9, thereby inhibiting terminal complement-mediated intravascular hemolysis in PNH, complement-mediated thrombotic microangiopathy in aHUS, and presumed reduction of terminal complement C5b-9 deposition at the neuromuscular junction in gMG and in NMOSD.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Vyvgart
  • Covered on 5 commercial plans
  • PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
View full coverage details ›
Soliris
  • Covered on 5 commercial plans
  • PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
View full coverage details ›
UnitedHealthcare
Vyvgart
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
View full coverage details ›
Soliris
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
View full coverage details ›
Humana
Vyvgart
  • Covered on 0 commercial plans
  • PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
View full coverage details ›
Soliris
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Myasthenia Gravis - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Soliris.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
VyvgartView full Vyvgart profile
SolirisView full Soliris profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.